Portal de investigação
Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Sousa, C
- Jacob, M
- Almeida, L
- Santos, V
- Araújo, D
- Magalhaes, A
- Cirnes, L
- Moura, CS
- Queiroga, H.
- Cruz Martins, N.
Unidades de investigação
Abstract
Background: Osimertinib efficacy in pre-treated patients with epidermal growth factor receptor (EGFR) T790M-mutated non-small cell lung cancer (NSCLC) has been demonstrated in clinical trials, but real-world data, particularly regarding resistance profile, remains limited. This study aims to analyze the resistance mechanisms acquired after treatment with Osimertinib. Methods: Clinical outcomes and molecular results from re-biopsies at the time of osimertinib progression of EGFR T790M-mutated NSCLC patient were analyzed. Results: Twenty-one patients with stage IV adenocarcinoma were included [median 69 years; 57.1% female; 85.7% never-smokers; 23.8% ECOG performance status (PS) >= 2]. Median PFS and OS were 13.4 (95% CI: 8.0-18.9) and 26.4 (95% IC: 8.9-43.8) months, respectively. At the time of analysis, 10 patients had tumor progression (47.6%). T790M loss occurred in 50%, being associated with earlier progression (median PFS 8.1 vs. 21.4 months, p = 0.011). Diverse molecular alterations were identified, including C797S mutation (n = 1), PIK3CA mutation (n = 2), MET amplification (n = 1), CTNNB1 mutation (n = 1), and DCTN1-ALK fusion (n = 1). Histological transformation into small cell carcinoma occurred in one patient. Conclusions: This real-world life study highlights the relevance of re-biopsy at the time of disease progression, contributing to understand resistance mechanisms and to guide treatment strategies.
Dados da publicação
- ISSN/ISSNe:
- 2234-943X, 2234-943X
- Tipo:
- Article
- Páginas:
- -
- Link para outro recurso:
- www.scopus.com
Frontiers in Oncology Frontiers Media S.A.
Citações Recebidas na Web of Science: 3
Citações Recebidas na Scopus: 3
Documentos
- Não há documentos
Filiações
Keywords
- non-small cell lung cancer; EGFR T790M mutation; osimertinib; resistance; real-world data; next generation sequencing
Financiamento
Proyectos asociados
Fibrosing ILD Biomarkers That Rule Acceleration (FIBRALUNG) -NCT05635032
Investigador Principal: Hélder Novais e Bastos
Estudo Observacional Académico (FIBRALUNG) . FCT . 2021
Doença do Refluxo Gastro-esofágico e Doença Pulmonar
Investigador Principal: Venceslau José Coelho Pinto Hespanhol
Estudo Clínico Académico (Refluxo Gastro-esofágic) . 2020
A importância do diagnóstico na Fibrose Pulmonar Idiopática
Investigador Principal: Venceslau José Coelho Pinto Hespanhol
Estudo Clínico Académico (FPI) . 2020
Chronic Bronchopulmonary aspergillosis patients with underlying chronic obstructive pulmonary disease: providing grounds for biomarkers search through clinical phenotyping
Investigador Principal: Hélder Novais e Bastos
Estudo Clínico Académico . 2020
Non-invasive assessment of Benign Tracheal Stenosis.
Investigador Principal: Hélder Novais e Bastos
Estudo Clínico Académico . 2020
Imunoterapia no cancro do pulmão: PD-L1, biomarcador preditivo?
Investigador Principal: Venceslau José Coelho Pinto Hespanhol
Estudo Clínico Académico . 2020
Citar a publicação
Fernandes M,Sousa C,Jacob M,Almeida L,Santos V,Araújo D,Bastos H,Magalhaes A,Cirnes L,Moura CS,Queiroga H,Cruz N,Hespanhol V. Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer. Front. Oncol. 2021. 11. 602924. IF:5,738. (2).
